In two recently published papers, a scientific reports on the discovery and implementation of a new, more efficient method for generating an important brain stem cell in the laboratory. The studies were published in Nature Communications and Stem Cell Reports.
“Making these specialized brain stem cells on a large scale at high purity from pluripotent stem cells gives us a powerful tool to study previously inaccessible normal and diseased tissues in the central nervous system,” said the senior author of the two papers. “We applied our technology to genetic models of myelin disease, which resulted in the discovery of a chemical compound that helps diseased myelin-producing cells to survive.”
Myelin, a fatty substance produced by cells called oligodendrocytes, coats nerve fibers and enables electrical signaling in the brain and facilitates normal neurological function.
Induced pluripotent stem cells are master cells that can potentially produce any cell the body needs. They are generated directly from existing adult cells. Embryonic stem cells are also pluripotent.
As reported in Nature Communications, researchers developed a new methodology to generate large quantities of oligodendrocytes and their progenitor cells—known as oligodendrocyte progenitor cells or OPCs—from mouse embryonic stem cells and induced pluripotent stem cells.
Many genes and cellular processes have been associated with oligodendrocyte dysfunction, but scientists have typically needed to make mutant mice to investigate these processes, often involving expensive, multi-year studies to examine a single aspect of this biology. To address this problem, the team developed a rapid and highly efficient method for generating OPCs and oligodendrocytes from pluripotent stem cells from any genetic background—providing new access to these relatively inaccessible brain cells in healthy and diseased states.
In Stem Cell Reports, the researchers leveraged this OPC generation technology to provide new insights and therapeutic strategies for a fatal genetic disorder of myelin, Pelizaeus Merzbacher disease (PMD). The team found that there was an unexpectedly early critical phase in PMD-affected cells characterized by endoplasmic reticulum stress and cell death as OPCs exit their progenitor state.
The endoplasmic reticulum is the part of the cell involved in the processing of protein. In PMD, which almost exclusively affects male children, oligodendrocytes are lost and myelin is not properly formed in the brain and spinal cord. Due to their diseased myelin, children with PMD exhibit often-debilitating problems of coordination, motor skills, verbal expression and learning. Due to the disease’s severity, patients typically die before adulthood.
To overcome this early cell death in PMD cells, the team screened thousands of drug-like compounds and found that one, known as Ro 25-6981, was especially successful in rescuing the survival of PMD oligodendrocytes in mouse and human cells in the laboratory and in PMD mice.
The team’s findings have implications beyond PMD. Numerous neurological and psychiatric diseases are characterized by myelin loss or dysfunction, including multiple sclerosis, spinal cord injury and schizophrenia. Measures to regenerate or restore myelin could offer patients hope in these and numerous other disorders affecting the brain and spinal cord.